Cabbacis Inc. Reveals Groundbreaking iBlend™ Clinical Findings
Transformative Results from iBlend™ Clinical Trials
iBlend with 20 Percent Hemp Significantly Reduced Exhaled Carbon Monoxide (CO) Levels Over Reduced-Nicotine Cigarette Without Hemp
Cabbacis, a U.S. federally-licensed tobacco manufacturer dedicated to developing harm-reduction products under the iBlend™ brand, has effectively demonstrated through a recent clinical trial that its patented iBlend™ cigarettes achieved significant satisfaction ratings and notably reduced cravings for traditional brand cigarettes.
Study Overview
Cabbacis engaged the Rose Research Center to conduct a pilot study involving 16 participants. They exclusively used four variants of reduced-nicotine tobacco cigarettes during a series of 3-hour sessions after a period of overnight abstinence from their regular brand. Each cigarette type included approximately 95 percent less nicotine compared to mainstream American brands. The experimental groups included three iBlend™ variants with varying hemp content (5%, 10%, and 20%), and a fourth variant that contained no hemp at all.
Impact on Cravings and Satisfaction
This study measured the participants' perceptions and behavioral changes associated with their smoking habits. Participants across all four cigarette types reported a significant reduction in cravings for their usual cigarettes, maintaining this relief throughout the duration of the study. The satisfaction levels indicated on the standardized mCEQ questionnaire surpassed those recorded in existing literature regarding other reduced-nicotine products.
Lowering Harmful Emissions
Interestingly, an unexpected positive outcome of the trial was the reduction in exhaled carbon monoxide (CO) levels among users of the hemp-infused cigarettes compared to those using the non-hemp variant. The most substantial reduction occurred with the iBlend™ variant containing 20% hemp, meeting statistical significance at the 95 percent confidence interval.
Expert Opinions on Findings
Dr. Michael Moynihan, Cabbacis's VP of R&D, expressed satisfaction with the findings of this study. They affirm that reduced-nicotine cigarettes infused with hemp resonate with tobacco smokers' preferences and contribute significantly to craving reduction. Dr. Moynihan emphasized the necessity for smokers to choose reduced-nicotine options for effective smoking reduction and nicotine exposure. This data will underpin future larger-scale studies necessary for submissions to regulatory bodies.
Future Regulatory Changes
Recent regulatory discussions have emphasized the FDA's initiative to establish rules that may limit nicotine content in cigarettes to minimally or nonaddictive levels, which aligns well with Cabbacis's product developments. Should Cabbacis submit the required applications, the path for the commercialization of reduced-nicotine iBlend™ cigarettes opens up, providing smokers with diverse, enjoyable options in the market.
Understanding Cabbacis’s Commitment
Cabbacis remains dedicated to producing reduced-nicotine cigarettes and vaporizer products, ensuring these offerings are primarily tobacco-based while incorporating hemp. The company also plans to release tobacco products without hemp.
Research Backing Product Development
Numerous independent studies have indicated that reduced-nicotine cigarettes contain about 95 percent less nicotine compared to traditional options. Evidence shows that smokers generally reduce their cigarette intake, lower their dependency, and even double their quit attempt rates due to these products. The incorporation of hemp flower in the reduced-nicotine offerings may enhance acceptability among consumers and boost their effectiveness through non-psychoactive cannabinoids.
A Global Perspective
Cabbacis LLC boasts an expansive patent portfolio, featuring 35 issued patents and various pending applications globally, covering regions with a significant smoking population such as the U.S., Europe, Asia, and South America. The company is a fully owned subsidiary of Cabbacis Inc., which is committed to making strides in public health and smoking cessation solutions.
Frequently Asked Questions
What is Cabbacis known for?
Cabbacis is recognized for its commitment to developing reduced-nicotine tobacco products and harm-reduction technology, particularly under the iBlend™ brand.
How do iBlend™ cigarettes work?
iBlend™ cigarettes are designed to enhance smoking satisfaction while significantly lowering nicotine content and harmful emissions like carbon monoxide.
What were the results of the recent clinical trials?
The trials indicated significant reductions in cravings for regular cigarettes and produced lower CO levels when using hemp-infused variants.
What is the future direction for Cabbacis?
Cabbacis aims to expand its product offerings both in the U.S. and international markets while pursuing larger studies to support FDA submissions.
How can I learn more about Cabbacis?
For more information, visit the official Cabbacis website or reach out via their media contact email.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
